Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pharmacyte Biotech Inc (PMCB)

Pharmacyte Biotech Inc (PMCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,622
  • Shares Outstanding, K 20,721
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,550 K
  • 60-Month Beta -0.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade PMCB with:

Options Overview Details

View History
  • Implied Volatility 109.85% ( +1.21%)
  • Historical Volatility 51.24%
  • IV Percentile 41%
  • IV Rank 15.57%
  • IV High 409.12% on 10/04/21
  • IV Low 54.66% on 09/24/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 321
  • Put/Call OI Ratio 8.06
  • Today's Open Interest 10,812
  • Open Int (30-Day) 9,489

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/22
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +15.31%
on 05/12/22
2.37 -4.64%
on 05/04/22
+0.11 (+5.12%)
since 04/22/22
3-Month
1.85 +22.16%
on 04/20/22
2.51 -9.96%
on 04/19/22
+0.35 (+18.32%)
since 02/24/22
52-Week
1.79 +26.26%
on 02/24/22
21.45 -89.46%
on 06/28/21
-17.24 (-88.41%)
since 05/24/21

Most Recent Stories

More News
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®...

PMCB : 2.26 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company. It is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). The Company's patented technology is...

See More

Key Turning Points

3rd Resistance Point 2.40
2nd Resistance Point 2.35
1st Resistance Point 2.30
Last Price 2.26
1st Support Level 2.20
2nd Support Level 2.15
3rd Support Level 2.10

See More

52-Week High 21.45
Fibonacci 61.8% 13.94
Fibonacci 50% 11.62
Fibonacci 38.2% 9.30
Last Price 2.26
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar